NNIT partners with global biopharma company for regulatory registration management
Charlie Blackie-Kelly | October 24, 2025 | News story | Business Services |Â Â IT, NNIT, digital solutions, regulatoryÂ
NNIT, a Danish provider of digital software and IT services, has entered a long-term strategic partnership with a global biopharmaceutical company to support the implementation of advanced digital solutions.
Although the biopharma partner remains undisclosed, NNIT confirmed that the new engagement builds on an existing collaboration, following the completion earlier this year of a regulatory submission solution.
The latest phase focuses on enhancing the management of regulatory registration processes and is scheduled to go live in March 2027. NNIT’s scope of work includes project management, process engineering, system integration, testing, organisational change management and training.
Over the course of their ten-year partnership, NNIT has delivered several projects for the client, including enterprise content modernisation initiatives and transactional platform upgrades across its human and animal health divisions.
“We have worked side-by-side with this global leader for more than ten years, not just as a technology supplier, but as a strategic partner. Together, we’ve tackled some of the most complex transformation programs, ensuring that each initiative supports broader business and regulatory goals.
“This new regulatory registration project reflects the strength of that collaboration: Navigating budget realities while safeguarding innovation, governance, and compliance which are the foundations for long-term success,” says David Narings, sales executive, North and Central Europe, NNIT.
Related Content
MIT-developed algorithm seeks to accelerate drug approvals during COVID-19 pandemic
A study emerging from the Massachusetts Institute of Technology (MIT) and published in the Harvard …
WHO confirm Tanzania FDA as Africa’s first well-functioning regulatory body
Tanzania has become the first country in Africa to achieve a well-functioning regulatory system for …
Study reveals “concerning” low standards of type 2 diabetes drugs in India
In what they believe is the first study of its kind, a team of researchers …
